Additional details will be shared at BioNTech’s Innovation Series R&D Day event on 14 November 2024 MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE)--BioNTech SE(Nasdaq: BNTX, “BioNTech”) andBiotheus(“Biotheus”) today announced the signing of a definitive agreement for t...
We will continue to follow the data generated by our pipeline to ensure we are investing appropriately to drive innovation and create value. Next, SG&A. We expect SG&A expenses to be in the range of 650 million euros to 750 million euros. We are anticipating an increase compared to 2024 as...
映恩生物本次香港IPO引入基石投资者包括BioNTech SE、LAV Star、Lake Bleu Prime Healthcare Master Fund Limited及Lake Bleu Innovation Healthcare Master Fund Limited、TruMed Healthcare Master Fund、ABS Direct Equity Fund LLC Asia Series 11及 TruMed Health Innovation Fund LP、富国资产管理(香港)有限公司及...
映恩生物本次香港IPO引入基石投资者包括BioNTech SE、LAV Star、Lake Bleu Prime Healthcare Master Fund Limited及Lake Bleu Innovation Healthcare Master Fund Limited、TruMed Healthcare Master Fund、ABS Direct Equity Fund LLC Asia Series 11及 TruMed Health Innovation Fund LP、富国资产管理(香港)有限公司及...
So I think we're going to provide more details at our innovation series week in terms of the paths to market. But I think what we can see is that we do think that small cell lung cancer to be one of the leading indications that we're looking at very closely. We initiated a Phase...